Gefitinib, erlotinib and icotinib were approved for the treatment of NSCLC, while lapatinib, which inhibits EGFR and HER2 kinases, is used in combination therapy for HER2-positive metastatic breast cancer. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.